Mode
Text Size
Log in / Sign up

GnRHa treatment in familial hCG syndrome associated with concurrent beta-hCG elevation in blood and CSF

GnRHa treatment in familial hCG syndrome associated with concurrent beta-hCG elevation in blood and …
Photo by National Institute of Allergy and Infectious Diseases / Unsplash
Key Takeaway
Note concurrent beta-hCG elevation in familial hCG syndrome may mimic malignancy.

A case report details the management of an 8-year-9-month-old girl presenting with central precocious puberty. The patient, along with her asymptomatic mother and prepubertal younger brother, received treatment with a gonadotropin-releasing hormone agonist (GnRHa). The setting was a hospital, involving a sample size of three individuals across the family unit.

During treatment, serum beta-hCG levels in the patient were elevated, ranging from 132.1 to 136.3 IU/L as measured by Roche Elecsys. Concurrently, cerebrospinal fluid beta-hCG levels were elevated at 103.22 IU/L using Abbott Architect. Elevated beta-hCG was also detected in the mother (43.79 mIU/mL) and the younger brother (64.58 mIU/mL), utilizing Abbott detection methods. Whole-exome sequencing yielded negative results for the family.

Imaging and pathological examinations identified a pineal cyst without evidence of tumor in the patient, while pathological examination noted a central neurocytoma. Oncological treatments were ceased during the course of the case. The primary outcome observed was the concurrent elevation of beta-hCG in blood and cerebrospinal fluid, which aided in the diagnosis of familial hCG syndrome and differentiation from intracranial malignancy. Evaluation of hCG variants by diverse detection antibodies was also conducted.

Safety data regarding adverse events or tolerability were not reported in the provided details. The study is a single case report, limiting the generalizability of these findings. Clinicians should recognize that elevated beta-hCG in this context may indicate familial hCG syndrome rather than a neoplastic process, particularly when family members also exhibit elevated levels.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedMar 2026
View Original Abstract ↓
ObjectiveTo describe a rare pediatric case of familial human chorionic gonadotropin (hCG) syndrome presenting with concurrent elevation of beta-hCG (β-hCG) in both blood and cerebrospinal fluid (CSF). This report aims to expand the phenotypic spectrum of this condition and discuss diagnostic challenges to avoid misdiagnosing this benign disorder as an intracranial malignancy.MethodsClinical data were collected from the proband, an 8-year-9-month-old girl presenting with central precocious puberty (CPP) and unexplained hCG elevation. To evaluate the differential recognition of hCG variants by diverse detection antibodies, serum and CSF β-hCG levels were cross-monitored using both Abbott Architect and Roche Elecsys platforms. Additional evaluations included magnetic resonance imaging (MRI), computed tomography (CT), and pathological examination. Whole-exome sequencing (WES) and family screening of first-degree relatives were conducted to identify the etiology. A literature review regarding familial hCG syndrome was also conducted.ResultsThe patient was initially diagnosed with CPP due to breast development and accelerated growth. During routine screening to exclude tumor-associated precocious puberty, she was found to have elevated serum β-hCG (132.1–136.3 IU/L, Roche Elecsys) and was referred to our hospital. Imaging revealed a pineal cyst without evidence of tumor. Both serum and CSF β-hCG levels were elevated (45.58 and 103.22 IU/L, respectively; Abbott Architect), with CSF levels exceeding serum. Despite chemotherapy, radiotherapy, and pineal cyst resection (histology: central neurocytoma), hCG remained persistently elevated. Given the benign clinical course and lack of therapeutic response, segregation analysis was subsequently performed. Elevated serum β-hCG levels were identified in the patient’s asymptomatic mother and prepubertal younger brother (43.79 and 64.58 mIU/mL, respectively; Abbott). Whole-exome sequencing was negative. Familial hCG syndrome was finally diagnosed, and it was determined that her CPP was an independent, concurrent condition. Oncological treatments were ceased, and the girl continued gonadotropin-releasing hormone agonist (GnRHa) treatment.ConclusionThis case report describes a novel clinical finding in familial hCG syndrome characterized by concurrent elevation of β-hCG in both serum and CSF. This finding significantly expands the phenotypic spectrum of this benign condition.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.